乳腺癌耐药蛋白在乳腺癌组织中的表达及与预后关系

目的研究乳腺癌耐药蛋白（Breast cancer resistance protein，BCRP）在乳腺癌组织中的表达，评估其在乳腺癌预后中的作用。方法采用免疫组织化学方法（Immunohistochemistry，IHC）检测47例手术切除的乳腺癌组织中BCRP的表达，并分析其与临床、病理特征的关系及对预后的影响。结果（1）BCRP在乳腺癌组织中的阳性表达率为55．3％（26／47例），其中高表达者13例（27．7％）；（2）激素受体阳性者BCRP表达水平明显高于激素受体阴性者（P〈0．05），BCRP表达与月经状况、肿瘤大小、腋淋巴结转移和组织分级均无关（P〉0．05）；（3）Kaplan—Meier生存分析结果表明BCRP和无病生存期相关（P〈0．05），但和总生存期无关（P〉0．05）；（4）Cox单因素分析显示肿瘤大小和BCRP表达与无病生存期明显相关（P〈0．05），而肿瘤大小和总生存期也明显相关（P〈0．05）；在多因素分析中BCRP表达仅和无病生存期明显相关，此外腋淋巴结转移与无病生存期和总生存期均明显相关（P〈0．05）。结论BCRP在乳腺癌组织中具有较高的表达水平，但与乳腺癌患者预后无关。

The prognostic significance of breast cancer resistance protein expression in primary breast carcinoma

Objective Intrinsic and/or acquired resistance was the major obstacle to overcome in the treatment of patients with breast cancer. The aim of the present study was to investigate the relationship between the expression of breast cancer resistance protein（BCRP） with the clinicopathologic characteristics and the prognosis in primary breast cancer patients. Methods Expression of BCRP in 47 breast cancer patients was determined by immunohistochemistry on formalin - fixed, paraffin - embedded tumor section. Results （ 1 ） BCRP expression was observed in 26 of 47（55.3% ）. （2）No relation can be established between expression of BCRP and other clinicopathologic parameters. （3） Kaplan - Meier analyses revealed that BCRP expression only associated with disease- free survival（DFS） and didn＇t with overall survival （OS）. （4）In one -factor Cox analysis, tumor size and BCRP - positive staining was associated with DFS （ P 〈 0.05 ）. In addition, tumor size also associated with OS（ P 〈 0.05 ）. In multivariate Cox regression analysis, BCRP expression only associated with DFS. Lymph node metastasis was independent prognostic factor for DFS and OS（ P 〈 0.05 ）. Conclusions Our results suggested that BCRP is frequently expression in primary breast cancer,but BCRP is not a poor prognostic factor in patients with breast cancer.